Mylan Fights FDA On Teva's Provigil Market Rights

Law360, Washington (April 18, 2012, 6:14 PM EDT) -- Mylan Inc. asked a federal judge Wednesday to block the U.S. Food and Drug Administration's decision giving Teva Pharmaceuticals USA Inc. 180-day exclusivity to market a generic version of Provigil, arguing Teva and its affiliate Cephalon Inc. had worked together to stymie generic competition of the Cephalon sleep disorder drug.

Mylan is requesting a preliminary injunction in the case to halt an FDA decision giving Teva exclusive rights to market a generic version of Provigil, or modafinil, despite Mylan's 2002 abbreviated new drug application for a...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

MYLAN PHARMACEUTICALS INC. v. SEBELIUS et al


Case Number

1:12-cv-00524

Court

District Of Columbia

Nature of Suit

Other Statutory Actions

Judge

Ellen S. Huvelle

Date Filed

April 4, 2012

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.